ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors ; volume:131 ; number:5 ; day:4 ; month:7 ; year:2024 ; pages:905-917 ; date:9.2024
British journal of cancer ; 131, Heft 5 (4.7.2024), 905-917, 9.2024
- Urheber
-
Smith, Hannah L.
Willmore, Elaine
Prendergast, Lisa
Curtin, Nicola J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-024-02745-0
- URN
-
urn:nbn:de:101:1-2411172143525.568135691805
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Smith, Hannah L.
- Willmore, Elaine
- Prendergast, Lisa
- Curtin, Nicola J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
PARP inhibitors
Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
PARP inhibitors
Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
PARP inhibitors
Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors